To assess impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant
Latest Information Update: 24 Aug 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 24 Aug 2022 New trial record
- 01 Aug 2022 Results published in the British Journal of Haematology